-
Douglas Kojetin
Dr. Douglas Kojetin is a leader in structural pharmacology whose work focuses on the molecular mechanisms behind drug action, particularly those targeting nuclear receptors—a class of proteins that regulate gene expression and play pivotal roles in diseases like cancer, inflammation, and…
-
Vanderbilt-discovered cancer killing compound is now available through Boehringer Ingelheim open science portal opnMe
Researchers in the lab of Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research, have added BI-0474 as the second molecule co-discovered by Vanderbilt to the open science portal opnMe.com, an initiative being driven by biopharmaceutical company Boehringer Ingelheim.